Analysts Observing Recap: Viking Therapeutics, Inc
Post# of 22759
Posted On: 04/11/2016 8:40:10 AM
Analysts Observing Recap: Viking Therapeutics, Inc. (NASDAQ:VKTX) , Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
April 11, 2016Eldred Matthew Healthcare0
Viking Therapeutics, Inc. (NASDAQ:VKTX) diminished -37.31%, closing at $1.21 after floating between $1.06 and $1.24. The company has market capitalization of $11.71M. It has twelve month low of $1.06 and twelve month high of $10.23.
The recent traded volume of 6.73 million shares higher than its average volume of 197.12 thousand shares. Analyst expected twelve month price target of $11.75.
During the most recent trading day, the stock’s price shifted up +14.15% from its 52-week low and -88.17% lower from its 52-week high. The stock’s price moved below its 200 day moving average of $3.32. The stock is currently trading down its SMA 50 of $1.73.
In the liquidity ratio analysis; debt to equity ratio was 0.25 while current ratio was 7.70. The company has the institutional ownership of 0.50 %. The stock’s RSI amounts to 39.27.
Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical firm focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, recently reported the pricing of an underwritten public offering of 7,500,000 shares of its ordinary stock and warrants to purchase up to 7,500,000 shares of its ordinary stock at a public offering price of $1.25 per share of ordinary stock and related warrant, for total predictable gross proceeds to Viking of about $9,375,000, before deducting underwriting discounts, commissions, and other offering expenses.
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 3 Analysts. 0 analysts have suggested “Sell” for the company. 0 analysts have rated the company as a “Hold”. Overweight rating was given by 0 analysts and Underweight rating was given by 0 analysts.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) after beginning at $162.33, closed at $156.36 by cutting down -4.56% in recent trading session. Most recent session’s volume of 3.12 million shares greater than its average volume of 842.11 thousand shares. The company has market value of $3.80B.
Analysts have consensus one year price target of $250.50.
During the last trading session, the stock’s price changed +7.18% above its 200 day moving average of $145.88 and moving +24.13% upbeat it’s SMA 50 of $125.96.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid, a bile acid analog, that completed Phase III clinical trials for the treatment of primary biliary cholangitis and Phase II clinical trials for the treatment of nonalcoholic fatty liver disease;
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 14 Analysts. 1 analyst has suggested “Sell” for the company. 3 analysts have rated the company as a “Hold”. Overweight rating was given by 1 analysts and Underweight rating was given by 1 analysts.
EPS growth ratio for the past five years was 59.20 %. Return on equity (ROE) was noted as 37.80%. The stock’s institutional ownership stands at 77.50%. The corporation generated income of $ 226.40M in past 12 months.
April 11, 2016Eldred Matthew Healthcare0
Viking Therapeutics, Inc. (NASDAQ:VKTX) diminished -37.31%, closing at $1.21 after floating between $1.06 and $1.24. The company has market capitalization of $11.71M. It has twelve month low of $1.06 and twelve month high of $10.23.
The recent traded volume of 6.73 million shares higher than its average volume of 197.12 thousand shares. Analyst expected twelve month price target of $11.75.
During the most recent trading day, the stock’s price shifted up +14.15% from its 52-week low and -88.17% lower from its 52-week high. The stock’s price moved below its 200 day moving average of $3.32. The stock is currently trading down its SMA 50 of $1.73.
In the liquidity ratio analysis; debt to equity ratio was 0.25 while current ratio was 7.70. The company has the institutional ownership of 0.50 %. The stock’s RSI amounts to 39.27.
Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical firm focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, recently reported the pricing of an underwritten public offering of 7,500,000 shares of its ordinary stock and warrants to purchase up to 7,500,000 shares of its ordinary stock at a public offering price of $1.25 per share of ordinary stock and related warrant, for total predictable gross proceeds to Viking of about $9,375,000, before deducting underwriting discounts, commissions, and other offering expenses.
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 3 Analysts. 0 analysts have suggested “Sell” for the company. 0 analysts have rated the company as a “Hold”. Overweight rating was given by 0 analysts and Underweight rating was given by 0 analysts.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) after beginning at $162.33, closed at $156.36 by cutting down -4.56% in recent trading session. Most recent session’s volume of 3.12 million shares greater than its average volume of 842.11 thousand shares. The company has market value of $3.80B.
Analysts have consensus one year price target of $250.50.
During the last trading session, the stock’s price changed +7.18% above its 200 day moving average of $145.88 and moving +24.13% upbeat it’s SMA 50 of $125.96.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid, a bile acid analog, that completed Phase III clinical trials for the treatment of primary biliary cholangitis and Phase II clinical trials for the treatment of nonalcoholic fatty liver disease;
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 14 Analysts. 1 analyst has suggested “Sell” for the company. 3 analysts have rated the company as a “Hold”. Overweight rating was given by 1 analysts and Underweight rating was given by 1 analysts.
EPS growth ratio for the past five years was 59.20 %. Return on equity (ROE) was noted as 37.80%. The stock’s institutional ownership stands at 77.50%. The corporation generated income of $ 226.40M in past 12 months.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼